Alnylam Pharmaceuticals (ALNY) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $16.26
- Estimate
- $2.25
- Surprise
- +623.0%
- Revenue (period 2026-09-30)
- $1.46B
- Score at report (before → after)
- 6.7 → 6.8/10
Revenue source: xbrl.
How the report landed
Alnylam Pharmaceuticals (ALNY) beat the $2.25 estimate with adjusted EPS of $16.26 — a large 623.0% upside surprise. TrendMatrix's engine moved from Sell (6.7/10) to Hold at 6.8/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ALNY Buy (Wait) at 6.6/10.
2 of the last 4 quarters beat the estimate; this quarter's +623.0% surprise compares with a +156.9% four-quarter average. Next scheduled report: 2027-02-11.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.2 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Cyclical risk: PE expanding 2.0x (earnings normalizing)
- Consecutive earnings misses (2)
- Negative momentum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $147.82
- Entry target
- $141.45
- Price target
- $256.47
- Stop
- $131.55
- Upside to target
- +73.5%
- Reward-to-risk
- 6.7:1
Forward estimates sit below the trailing run-rate (15.1× forward vs 7.5× trailing) — consensus expects earnings to decline from here.
Model outputs from TrendMatrix’s engine as of 2026-11-19 — shown for context, not personalized investment advice.
ALNY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $20.01B
- P/E (fwd)
- 15.1
- P/E (ttm)
- 7.5
- 52-week range
- $147.58–$479.79
- Off 52-week high
- 69.2%
- RSI (14)
- 35
- Volume vs avg
- 0.63×
- Score today
- 6.6/10